PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Therapeutic Use
- Acronyms PROPHETIC
- 14 Dec 2021 Status changed to discontinued according to ClinicalTrials.gov record (Not able to meet recruitment targets)
- 25 Aug 2021 Planned number of patients changed from 100 to 40.
- 07 Jul 2020 New trial record